

Teams and Projects

Washington University at St Louis

PI: Kooresh Shoghi (shoghik@mir.wustl.edu)

Project Title: Washington University Co-Clinical Imaging Research Resource

Project 1: [Triple Negative Breast Cancer](#)

Project 2: [ER2+/HER2- Breast Cancer](#)

Duke University

PI: Cristian Badea (Cristian.Badea@duke.edu)

Project: [The Duke Preclinical Research Resources for Quantitative Imaging Biomarkers](#)

MD Anderson Cancer Center

PI: Henry Charles Manning (HCManning@mdanderson.org)

Project: [MDACC Predict](#) (Previous [VU Predict](#))

University of Pennsylvania

PI: Rong Zhou (rongzhou@mail.med.upenn.edu)

Project: [Penn Quantitative MRI Resource for Pancreatic Cancer](#)

University of Michigan

PI: Brian D. Ross (bdross@umich.edu)

Project: [University of Michigan Quantitative Co-Clinical Imaging Research Resource](#)

Baylor College of Medicine*/UT Austin/Stanford

PI: Michael Lewis (mtlewis@bcm.edu)

Project: [Integrating Omics and Quantitative Imaging Data in Co-Clinical Trials to Predict Treatment Response in Triple Negative Breast Cancer](#)

University of California, San Francisco

PI: John Kurhanewicz (john.kurhanewicz@ucsf.edu)

Project: [Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized ¹³C MRI](#)

University of Washington*/Fred Hutchinson Cancer Research Center/Brigham and Women's Hospital

PI: Paul Kinahan (kinahan@uw.edu)

Project: [A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies](#)

Stanford University

PI: Daldrup-Link (heiked@stanford.edu)

Project: [Co-Clinical Research Resource for Imaging Tumor-Associated Macrophages](#)

A highlight of CIRP Projects

See Peehl DM, et al. **Animal Models and Their Role in Imaging-assisted Co-clinical Trials.** *Tomography* **2023**, 9, 657–680. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037611/>

Institution	Cancer/Disease	Model	Site	Disease Development	Therapy	Imaging
Baylor/UT Austin/Stanford	Triple-negative breast cancer	PDX	Orthotopic	2–6 weeks	Chemotherapy	mpMRI
Duke	Soft tissue sarcoma	GEMM	Orthotopic	Median 54 days	Immunotherapy Radiation Surgery	mpMRI CT
MDACC	Colorectal cancer	PDX	Subcutaneous	3 weeks	Targeted therapy	PET
Stanford	Osteosarcoma	xenografts	Orthotopic	2–3 weeks	Immunotherapy	T ₂ -weighted MRI
UCSF	Small cell neuroendocrine prostate cancer	PDX	Bone, liver	1–4.5 months to reach 0.3 cc	Chemotherapy	HP MRI, mpMRI
U Mich	Myelofibrosis	GEMM	Orthotopic	21 days	Targeted therapy	mpMRI
U Penn	Pancreatic ductal adenocarcinoma	GEMM	Orthotopic	17–19 weeks	Chemoimmuno& stromal-targeted therapy	mpMRI
U Wash	Non-small cell lung cancer	GEMM	Orthotopic	20–30 weeks	Immunotherapy	PET/CT
WUSTL	Triple-negative breast cancer	PDX	Orthotopic	4 weeks–6 months	Chemotherapy	PET/MRI
WUSTL	ER+ breast cancer	PDX	Orthotopic	~3–4 months	Endocrine therapy Targeted therapy	PET